Literature DB >> 3460172

Pharmacokinetics and metabolism of omeprazole in man.

C G Regårdh.   

Abstract

Four studies of the pharmacokinetics and metabolism of omeprazole are briefly discussed. Two of these were carried out in young healthy subjects and indicated that about 54% of an oral dose is available to the systemic circulation. The distribution of omeprazole after an intravenous dose was consistent with localization of a major fraction of the drug in the extracellular water, with about 25% restricted to the blood. Omeprazole was rapidly cleared and possessed the characteristics of a high clearance drug; insignificant amounts of 14C-omeprazole were excreted by the kidneys, though metabolites were excreted very rapidly. Six different metabolites were reported, the major one being hydroxy-omeprazole. Increasing the intravenous dose of omeprazole from 10 mg to 40 mg had no significant effect on the pharmacokinetic parameters determined. A study in patients with impaired renal function showed that this had little effect on the kinetics of omeprazole, though excretion of metabolites was significantly affected. A study of elderly healthy subjects suggested that the disposition characteristics of omeprazole are affected to some extent by age; further studies are needed to elucidate the clinical implications. Omeprazole has been reported to prolong the half-life of diazepam which may be due to inhibition of the demethylation of diazepam. The interaction of omeprazole with the kinetics of aminopyrine and antipyrine was much less pronounced.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3460172     DOI: 10.3109/00365528609090907

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  14 in total

1.  Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole.

Authors:  Z Hussein; G R Granneman; D Mukherjee; E Samara; D L Hogan; M A Koss; J I Isenberg
Journal:  Br J Clin Pharmacol       Date:  1993-11       Impact factor: 4.335

2.  Pharmacokinetics of various single intravenous and oral doses of omeprazole.

Authors:  T Andersson; C Cederberg; C G Regårdh; I Skånberg
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 3.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

4.  Evaluating a physiologically based pharmacokinetic model for prediction of omeprazole clearance and assessing ethnic sensitivity in CYP2C19 metabolic pathway.

Authors:  Sheng Feng; Yumi Cleary; Neil Parrott; Pei Hu; Cornelia Weber; Yongqing Wang; Ophelia Q P Yin; Jun Shi
Journal:  Eur J Clin Pharmacol       Date:  2015-03-24       Impact factor: 2.953

Review 5.  Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders.

Authors:  D McTavish; M M Buckley; R C Heel
Journal:  Drugs       Date:  1991-07       Impact factor: 9.546

6.  Parenteral control of gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.

Authors:  R Vinayek; W F Hahne; A R Euler; J A Norton; R T Jensen
Journal:  Dig Dis Sci       Date:  1993-10       Impact factor: 3.199

Review 7.  Renal effects of peptic ulcer therapy.

Authors:  E Burgess; D Muruve
Journal:  Drug Saf       Date:  1992 Jul-Aug       Impact factor: 5.606

8.  Gastroesophageal reflux in children: pathogenesis, prevalence, diagnosis, and role of proton pump inhibitors in treatment.

Authors:  Benjamin D Gold; James W Freston
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

9.  Pharmacokinetics of intravenous omeprazole in children.

Authors:  E Jacqz-Aigrain; M Bellaich; C Faure; J Andre; P Rohrlich; V Baudouin; J Navarro
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 10.  Risk-benefit assessment of omeprazole in the treatment of gastrointestinal disorders.

Authors:  W Creutzfeldt
Journal:  Drug Saf       Date:  1994-01       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.